Intestinal Failure Life Expectancy and Survival Rates

Life expectancy with intestinal failure varies enormously depending on age, the underlying cause, the type of care received, and whether a person can eventually wean off intravenous nutrition. A large UK study of adults with chronic intestinal failure found that patients lost roughly 17 extra years of life compared with the general population, with survival dropping to about 54% at ten years and 30% at twenty years. Children fare considerably better in the modern era, with survival rates now routinely exceeding 90% at specialized centers. Those numbers, though, represent averages across very different situations, and individual outlooks hinge on a cluster of factors that are worth understanding in detail.

What Intestinal Failure Means in Practice

Intestinal failure is defined by the European Society for Clinical Nutrition and Metabolism as a reduction of gut function below the minimum needed to absorb enough nutrients, water, and electrolytes to stay healthy, meaning the person requires intravenous supplementation to survive.¹ It is classified into three types. Type 1 is acute and self-limiting, often after surgery. Type 2 is a prolonged acute phase requiring weeks to months of intravenous feeding while the gut recovers. Type 3 is chronic, meaning a person depends on parenteral nutrition (PN) long-term, sometimes for life. When people ask about life expectancy with intestinal failure, they almost always mean type 3, and that is the focus of the survival data that follows.

Adult Survival Numbers

The clearest long-term data comes from a study tracking patients with type 3 intestinal failure in the United Kingdom. Survival was about 92% at one year, 69% at five years, 54% at ten years, and just under 30% at twenty years.² Compared with the general population of the same age and sex, mortality was more than seven times higher, and both men and women lost an average of about 17 years of life. Those figures include patients managed at a referral center with dedicated intestinal failure expertise, so outcomes at less experienced facilities may be worse.

A separate analysis of adults at a single tertiary intestinal rehabilitation program reported a five-year survival rate of about 82% and a ten-year rate of 68%.³ The main causes of death were bloodstream infections from central venous catheters, liver failure related to long-term parenteral nutrition, and complications following intestinal transplantation. A Danish study looking at hospitalized patients who required total parenteral nutrition for the first time painted a grimmer picture: only 58% were alive at an average follow-up of about a year and a half, with a mortality rate of 30 deaths per 100 patient-years.⁴ That study included patients with cancer and critical illness, which pulls survival down compared to cohorts restricted to chronic intestinal failure from benign causes.

The takeaway is that adult survival depends heavily on who is being studied. An otherwise healthy adult with short bowel syndrome from Crohn’s disease, managed at a specialized center, has a very different trajectory than an elderly patient with intestinal failure triggered by mesenteric vascular disease and multiple comorbidities.

Why Children Do So Much Better

Pediatric intestinal failure is a genuinely different story. Over the past two decades, multidisciplinary intestinal failure programs have pushed survival in children well above 90%, and most children now survive long-term.⁵ A Finnish national referral center reported a 15-year survival estimate of 91% among its first 100 pediatric patients, with roughly two-thirds weaned off parenteral nutrition within five years and nearly three-quarters weaned by ten years.⁶

These improvements have been dramatic enough that the focus of pediatric care has shifted from merely keeping children alive to managing long-term growth, development, and quality of life.⁷ Children’s guts also have a stronger capacity for adaptation, meaning the remaining bowel can grow and become more efficient at absorbing nutrients over time, which improves the odds of eventually coming off intravenous feeding altogether.

The improvement didn’t happen overnight. A study tracking 171 children showed that survival was significantly worse in the early 1990s compared with later cohorts, and the single most identifiable change between those eras was the creation of dedicated intestinal failure care teams.⁸ Being able to wean off parenteral nutrition and having more remaining small bowel were both independently linked to better survival.

What Determines an Individual’s Outlook

Across both children and adults, several factors consistently predict who lives longer and who faces greater risk.

Remaining bowel length: Adults with short bowel syndrome whose residual small bowel is less than 50 centimeters have worse survival than those with longer remnants.⁹ In children, having at least 10% of the expected bowel length is associated with better outcomes.¹⁰
Underlying cause: Intestinal failure caused by arterial infarction (a blood clot cutting off blood supply to the bowel) carries a worse prognosis than causes like Crohn’s disease or surgical complications.¹¹ In adults, an underlying cancer diagnosis significantly raises mortality risk.¹²
Bowel anatomy: Having an end stoma (where the remaining bowel empties into a bag rather than reconnecting to the colon) is an independent risk factor for death, because the colon’s water-absorption capacity is lost.¹³
Age and nutritional status: Older patients and those with a lower body mass index at the time parenteral nutrition begins have higher mortality.¹⁴
Access to specialized care: Being managed at a center with a dedicated intestinal rehabilitation program is repeatedly associated with better survival in both children and adults.¹⁵

The Complications That Shorten Lives

Long-term parenteral nutrition keeps people alive, but it introduces its own set of serious risks. The two biggest threats are catheter-related bloodstream infections and liver disease.

Catheter-related sepsis is the most common complication in patients on home parenteral nutrition, occurring at a rate of roughly 0.30 to 0.50 episodes per patient per year at experienced centers. It is fatal in about 2.5% of episodes and accounts for around half of all deaths directly attributable to home parenteral nutrition itself.¹⁶ Each infection also risks damaging or clotting the central vein where the catheter sits, and repeated clotting can eventually exhaust the available venous access sites. Losing central venous access is considered one of the most dire scenarios for someone dependent on intravenous nutrition, because it can make ongoing parenteral support impossible.¹⁷

Intestinal failure-associated liver disease (IFALD) is the other major concern. In adults, severe liver disease develops in a minority of patients, but in infants and neonates the risk is higher and progression to cirrhosis is more common.¹⁸ Children referred to intestinal rehabilitation programs with more advanced liver disease at the time of referral have both higher mortality and a lower chance of ever coming off parenteral nutrition.¹⁹ On a more encouraging note, advances in lipid formulations have improved IFALD outcomes. A study of children with short bowel syndrome and liver disease found a 97% transplant-free survival rate using a protocol that relied on low-dose soybean lipid emulsion, with 81% of children eventually achieving enteral autonomy.²⁰

Gut Adaptation and the Possibility of Weaning Off IV Nutrition

One of the most important factors in long-term prognosis is whether the remaining bowel can adapt sufficiently to absorb enough nutrients on its own. After a major bowel resection, the remnant intestine undergoes structural and functional changes: villi grow taller, crypts deepen, nutrient transporter activity increases, and transit slows down to give food more contact time with the absorptive surface.²¹ Gut hormones, particularly GLP-2, appear to drive much of this process, though the full picture remains unclear.²²

Adaptation is strongest in children and can continue for years. In adults, the degree of adaptation is generally more limited, but it still occurs and can sometimes allow a gradual reduction or even elimination of parenteral nutrition. The patients who manage to wean off intravenous feeding entirely have a fundamentally different risk profile, because they shed the ongoing catheter and liver disease risks that drive much of the excess mortality.

Drugs That Help Reduce Parenteral Nutrition Dependence

Teduglutide, a synthetic version of the gut hormone GLP-2, is the most significant pharmacological advance in intestinal failure management in recent years. It works by enhancing the natural adaptation process, stimulating growth and blood flow in the intestinal lining. A systematic review and meta-analysis found that about 64% of patients on teduglutide achieved at least a 20% reduction in their parenteral nutrition volume at six months, rising to about 77% at one year and 82% at two or more years.²³ A separate meta-analysis reported slightly different longer-term figures, with response rates reaching about 73% after two or more years and the proportion of patients achieving full enteral autonomy rising from about 13% at six months to 31% after two or more years.²⁴

A real-world retrospective study showed a similar pattern, with about 85% of patients responding to treatment and average parenteral support volumes dropping by roughly a third within six months and by half at twelve months.²⁵ While teduglutide does not cure intestinal failure for most patients, even a partial reduction in parenteral nutrition translates to fewer nights hooked up to an infusion pump, lower complication rates, and potentially a better long-term survival trajectory.

Surgical Options and When They Are Considered

Surgery enters the picture in two distinct ways: procedures that try to make the existing bowel work better, and intestinal transplantation as a last resort.

Bowel-lengthening procedures, including Serial Transverse Enteroplasty (STEP) and related techniques, are primarily used in children whose remaining bowel has become dilated. The idea is to reshape the dilated bowel into a longer, narrower tube to improve motility and absorption.²⁶ A multicenter study of STEP in children found that about 42% of those dependent on parenteral nutrition before surgery were weaned off completely afterward, while the remainder still needed PN but at reduced volumes.²⁷ Another series found that a majority of children who underwent STEP achieved enteral autonomy at mid-term follow-up.²⁸

Intestinal transplantation is reserved for patients who are failing on parenteral nutrition, typically due to life-threatening liver disease, loss of venous access, or recurrent severe infections. Survival after transplant has improved over the decades but remains modest compared to other solid organ transplants. International registry data showed one-year patient survival around 63% to 69% depending on the type of transplant, and the largest center reported five-year patient survival of about 48%.²⁹ Combined small bowel and liver transplantation, needed when IFALD has progressed to irreversible liver failure, offers roughly 50% survival at five years.³⁰ Because transplant outcomes are worse than well-managed home parenteral nutrition, it is viewed as a treatment for complications of intestinal failure rather than for intestinal failure itself.

The Trend Is Getting Better

One of the more reassuring aspects of the data is that survival has been improving steadily. In adults, home parenteral nutrition-related mortality has fallen over the past decade, even as the patient population has gotten older and more complex.³¹ In children, mortality has declined significantly over time, with the introduction of intestinal rehabilitation programs and newer lipid formulations (particularly omega-3-enriched products) each independently contributing to the drop.³² This means that survival figures drawn from older cohorts may understate the prognosis for someone diagnosed today.

Living With Intestinal Failure Beyond Survival

Survival statistics tell you how long people live, but they miss how people live. A systematic review of quality-of-life research found that adults on home parenteral nutrition consistently reported lower physical functioning compared to the general population.³³ Nightly infusions that run for 10 to 14 hours restrict sleep, travel, and spontaneity. Managing a central line at home requires strict sterile technique. Dehydration, electrolyte swings, and fatigue are common daily realities. The review also found that patients who could reduce their number of infusion nights per week reported better quality of life, which is one reason the partial reductions achieved with teduglutide matter even when they fall short of complete weaning.

Strikingly, the same review found no published studies examining the quality of life of family caregivers, a gap that speaks to how under-researched the human side of this condition remains. For a disease that requires a family member or partner to help with nightly infusions, troubleshoot pump alarms, and watch for signs of catheter infection, the absence of caregiver data is a significant blind spot.

How Care Delivery Is Changing

Getting to a specialized center matters, but geography can be a barrier. A retrospective study compared virtual visits to in-person visits for adults on home parenteral nutrition and found that virtual follow-up was no worse than in-person care for catheter-related complications or hospital readmissions.³⁴ That finding has practical implications: patients living far from a referral center may not need to travel as frequently for routine monitoring, while still getting the benefits of expert oversight. It does not replace the need for an experienced team, but it makes accessing one more feasible for people in rural or underserved areas.

The cost side is also worth noting. Home parenteral nutrition is expensive, and in the United States, Medicare eventually covers costs for more than 60% of all long-term survivors, with many patients qualifying for financial hardship waivers for copays.³⁵ Access to insurance and to specialized pharmacy services can shape outcomes in ways that clinical trials do not capture, because a patient whose supply chain is unreliable or whose catheter care training is inadequate faces risks that have nothing to do with biology.